TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 8330828
Drug: 2.4 mg
Normalized name: pectin 2.4 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2.4 mg glycerol trinitrate (GTN) administered in various forms (2 x 1.2 mg capsules; 6 x 0.4 mg puffs of an atomizer; 2.4 ml of an 0.1% infusion solution)
Study: 6101174
Drug: Propranolol (240
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propranolol (240 mg daily for two weeks)
Study: 16827683
Drug: Tacrolimus-based therapy
Normalized name: Tacrolimus
DrugBank: Tacrolimus (DB00864)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tacrolimus-based therapy (n = 33)
Study: 16827683
Drug: Cyclosporine microemulsion-based
Normalized name: cyclosporine microemulsion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cyclosporine microemulsion-based therapy (n = 33)
Study: 8689806
Drug: 2 mg
Normalized name: iodine 2 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 mg buprenorphine and 2 mg naloxone combined
Study: 25792802
Drug: Transdermal donepezil
Normalized name: donepezil Transdermal Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transdermal donepezil patch
Study: 23506277
Drug: 127.2 mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 127.2 mg lidocaine with 50 μg epinephrine plus 0.5 M mannitol (5 mL formulation)
Study: 23506277
Drug: 127.2 mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 127.2 mg lidocaine with 50 μg epinephrine (3.18 mL formulation)
Study: 21455087
Drug: Hydrocortisone (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hydrocortisone (100 mg) given at 2 doses 8 hrs apart
Study: 9173967
Drug: Hydrocortisone (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hydrocortisone (100 mg)
Study: 19653988
Drug: STD-14 (0.25
Approvals — FDA: no, EMA: no, PMDA: no
Description: STD-14 (0.25 mg/kg/day for 14 days)
Study: 19653988
Drug: STD-3 (0.25
Approvals — FDA: no, EMA: no, PMDA: no
Description: STD-3 (0.25 mg/kg/day for 3 days)
Study: 3891378
Drug: Slow-release furosemide
Approvals — FDA: no, EMA: no, PMDA: no
Description: Slow-release furosemide 30 mg daily
Study: 31780018
Drug: Craniosacral Therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Craniosacral Therapy (CST)
Study: 22901362
Drug: Olanzapine (5-20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Olanzapine (5-20 mg/d; mean dose = 13.5 mg/d)
Study: 22901362
Drug: Lithium (300-1,800
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lithium (300-1,800 mg/d; mean dose = 1,003.3 mg/d)
Study: 15910516
Drug: 5 mg
Normalized name: talc 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mg melatonin administered at 18:00 or 19:00 hours
Study: 15910516
Drug: Placebo administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo administered at 18:00 or 19:00 hours
Study: 9517367
Drug: Single oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single oral dose of carbamazepine (200-800 mg)
Study: 9517367
Drug: Multiple dosing
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multiple dosing of carbamazepine (400-800 mg twice daily for 14 days)
Study: 8038904
Drug: Sodium valproate
Normalized name: sodium valproate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sodium valproate (600 mg in three divided doses orally)
Study: 8038904
Drug: Naloxone (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Naloxone (10 mg as an iv bolus injection)
Study: 7762325
Drug: Suppressive therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Suppressive therapy
Study: 31012853
Drug: PFT-guided de-escalation
Normalized name: sangre de grado
Approvals — FDA: no, EMA: no, PMDA: no
Description: PFT-guided de-escalation of dual antiplatelet therapy (DAPT)
Study: 29912422
Drug: Standard treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard treatment with prasugrel for 12 months (control group)
Study: 21962461
Drug: Group treatment
Normalized name: Allergenic Extracts Intradermal Kit [9 SO. GRASS GROUP TREATMENT SET]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group treatment sessions (GT) of pelvic floor muscle training (PFMT) for 6 weeks, with two 1-hour sessions per week.
Study: 17360209
Drug: Nebulized albuterol
Normalized name: Albuterol
DrugBank: Albuterol (DB01001)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nebulized albuterol (2.5mg)
Study: 10673512
Drug: IM862 intranasal
Normalized name: influenza A virus (H1N1) antigen
Approvals — FDA: no, EMA: no, PMDA: no
Description: IM862 intranasal drops at a dose of 5 mg, given in two dosing schedules: 5 days on, 5 days off (n = 18)
Study: 10673512
Drug: IM862 intranasal
Normalized name: influenza A virus (H1N1) antigen
Approvals — FDA: no, EMA: no, PMDA: no
Description: IM862 intranasal drops at a dose of 5 mg, given every other day (n = 26)
Study: 1993279
Drug: Ethoglucid (0.565
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ethoglucid (0.565 g, 1% solution) weekly for 6 weeks, then monthly for 1 year
Study: 1993279
Drug: Keyhole-limpet haemocyanin
Normalized name: Keyhole limpet hemocyanin
DrugBank: Keyhole limpet hemocyanin (DB05299)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Keyhole-limpet haemocyanin (KLH) 1 mg subcutaneously, followed by bladder instillations of 30 mg weekly for 6 weeks, then monthly for 1 year
Study: 6394516
Drug: 50 mg
Normalized name: talc 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 mg captopril
Study: 7033946
Drug: 2.5 mg
Normalized name: biotin 2.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2.5 mg indapamide
Study: 29143355
Drug: Oral appliances
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral appliances with an occlusal flat table
Study: 26964901
Drug: 30 mg/mL
Normalized name: urea 30 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 mg/mL ketorolac buccal infiltration
Study: 24627629
Drug: No Treatment
Normalized name: NO
DrugBank: Nitric Oxide (DB00435)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: No Treatment
Study: 19675960
Drug: Cognitive Behavioral
Normalized name: Mahana Parallel Digital Cognitive Behavioral Therapy Mobile Application for Irritable Bowel Syndrome
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive Behavioral Therapy plus Motivational Interviewing (CBT + MI)
Study: 19675960
Drug: Cognitive Behavioral
Normalized name: Mahana Parallel Digital Cognitive Behavioral Therapy Mobile Application for Irritable Bowel Syndrome
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive Behavioral Therapy plus Psychoeducation (CBT + PE)
Study: 15671428
Drug: GIK infusion
Normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: GIK infusion for 24 hours plus usual care (n = 10,091)
Study: 10585975
Drug: Hydrocortisone treatment
Normalized name: Hydrocortisone
DrugBank: Hydrocortisone succinate (DB14545)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Hydrocortisone treatment (1 mg/kg/day for 9 days followed by 0.5 mg/kg/day for 3 days)
Study: 1832261
Drug: Glycopyrrolate (7
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glycopyrrolate (7 micrograms.kg‐1, single dose)
Study: 6619271
Drug: Domperidone (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Domperidone (10 mg, iv) administered at 1100 h
Study: 6619271
Drug: Domperidone (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Domperidone (10 mg, iv) administered at 2300 h
Study: 6376722
Drug: melphalan (8
Approvals — FDA: no, EMA: no, PMDA: no
Description: melphalan (8 mg/m2 perorally for four days) and prednisone (40 mg/m2 perorally for seven days, both every four weeks)
Study: 10571355
Drug: Topical anesthesia
Normalized name: Gelato Anesthetic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical anesthesia plus 0.5 ml intracameral balanced salt solution
Study: 1859055
Drug: Oral killed
Normalized name: Hongo Killer
DrugBank: Undecylenic acid (DB11117)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral killed Haemophilus influenzae vaccine
Study: 6138009
Drug: Buspirone hydrochloride
Normalized name: Buspirone Hydrochloride
DrugBank: Buspirone (DB00490)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Buspirone hydrochloride 30 mg
Study: 6138009
Drug: Buspirone hydrochloride
Normalized name: Buspirone Hydrochloride
DrugBank: Buspirone (DB00490)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Buspirone hydrochloride 60 mg
Study: 6138009
Drug: Buspirone hydrochloride
Normalized name: Buspirone Hydrochloride
DrugBank: Buspirone (DB00490)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Buspirone hydrochloride 90 mg
Study: 6138009
Drug: Buspirone hydrochloride
Normalized name: Buspirone Hydrochloride
DrugBank: Buspirone (DB00490)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Buspirone hydrochloride (30, 60, 90 mg)
Study: 31290965
Drug: Esketamine 56
Normalized name: ESKETAMINE
DrugBank: Esketamine (DB11823)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Esketamine 56 mg plus oral antidepressant
Study: 31290965
Drug: Placebo plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo plus oral antidepressant
Study: 28816150
Drug: Ipilimumab 3
Normalized name: Ipilimumab
DrugBank: Ipilimumab (DB06186)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Ipilimumab 3 mg/kg with WBRT (n=5)
Study: 28816150
Drug: Ipilimumab 10
Normalized name: Ipilimumab
DrugBank: Ipilimumab (DB06186)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Ipilimumab 10 mg/kg with SRS (n=11)
Study: 25413313
Drug: Adjuvant chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adjuvant chemotherapy with methotrexate, vinblastine, doxorubicin, and cisplatin (MVAC) in 27 patients with LVI-positive tumors.
Study: 16971315
Drug: Azithromycin 500
Normalized name: azithromycin 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Azithromycin 500 mg for 3 consecutive days a week for 1 month, then 250 mg every other day for 2 months
Study: 15179210
Drug: Beta-blocker (Metoprolol)
Normalized name: Beta Carotene
DrugBank: Beta carotene (DB06755)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Beta-blocker (Metoprolol)
Study: 11722956
Drug: Methionine intake
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methionine intake of 0 mg x kg(‐1) x d(‐1)
Study: 11722956
Drug: Methionine intake
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methionine intake of 6.5 mg x kg(‐1) x d(‐1)
Study: 21570870
Drug: Batroxobin plus
Normalized name: batroxobin
DrugBank: Batroxobin (DB09005)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Batroxobin plus aspirin (5 IU every other day for six doses)
Study: 21570870
Drug: Aspirin alone
Normalized name: Aspirin
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Aspirin alone (100 mg/d)
Study: 21570870
Drug: Batroxobin plus
Normalized name: batroxobin
DrugBank: Batroxobin (DB09005)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Batroxobin plus aspirin
Study: 11180027
Drug: 10 mg/70
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg/70 kg of morphine
Study: 11180027
Drug: 3.3 mg/70
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3.3 mg/70 kg of M6G
Study: 11180027
Drug: 30.6 mg/70
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30.6 mg/70 kg of M3G
Study: 11180027
Drug: 30.6 mg/70
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30.6 mg/70 kg of M3G with 10 mg/70 kg of morphine
Study: 9382506
Drug: Postoperative complications
Normalized name: combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Postoperative complications in radiation therapy group
Study: 8808186
Drug: Intravenous cyclophosphamide
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous cyclophosphamide (CTX)
Study: 21099157
Drug: Etching with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Etching with 10% citric acid‐3% FeCl(3) solution
Study: 18398348
Drug: Ramipril, 10
Normalized name: Ramipril, 10 mg oral capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ramipril, 10 mg once daily for 24 weeks
Study: 14570950
Drug: 250 mg
Normalized name: rutin 250 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 250 mg gefitinib
Study: 14570950
Drug: 500 mg
Normalized name: bran 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 500 mg gefitinib
Study: 14570950
Drug: Both doses
Normalized name: Bothrops atrox venom
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both doses of gefitinib
Study: 9598255
Drug: Propofol (2.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propofol (2.5 mg.kg‐1)
Study: 8678385
Drug: ipratropium bromide
Normalized name: Ipratropium Bromide
DrugBank: Ipratropium (DB00332)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: ipratropium bromide nasal spray 0.06% (two 42-micrograms sprays per nostril)
Study: 8678385
Drug: ipratropium bromide
Normalized name: Ipratropium Bromide
DrugBank: Ipratropium (DB00332)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: ipratropium bromide nasal spray 0.06%
Study: 30842084
Drug: Hydroxychloroquine (HCQ)
DrugBank: Hydroxychloroquine (DB01611)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Hydroxychloroquine (HCQ) treatment for more than 5 years
Study: 29342952
Drug: Cognitive behavioral
Normalized name: Mahana Parallel Digital Cognitive Behavioral Therapy Mobile Application for Irritable Bowel Syndrome
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive behavioral therapy (STreSS)
Study: 27724992
Drug: Oral spray
Normalized name: Oral Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral spray vitamin D3 (3000 IU daily for 4 weeks)
Study: 27724992
Drug: Capsule vitamin
Normalized name: vitamin A Oral Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Capsule vitamin D3 (3000 IU daily for 4 weeks)
Study: 18441679
Drug: Fenspiride in
Normalized name: fenspiride
DrugBank: Fenspiride (DB08979)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fenspiride in combination with broncholytic drugs for 6 months
Study: 16800987
Drug: combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: combination of LDL and UDA (LDL + UDA)
Study: 21262858
Drug: donepezil 5
Normalized name: donepezil 5 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: donepezil 5 mg
Study: 21262858
Drug: donepezil 7.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: donepezil 7.5 mg
Study: 7839518
Drug: Vitaria oxygen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitaria oxygen delivery system (75 mg sodium carbonate powder, max flow of 1 l/min for 15 minutes)
Study: 3147338
Drug: Topical application
Normalized name: Talc Topical application Powder
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical application of nitroglycerin (both TNL and ND)
Study: 26376805
Drug: Paroxetine (20-40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Paroxetine (20-40 mg)
Study: 10795116
Drug: Amitriptyline (75-150
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amitriptyline (75-150 mg)
Study: 1601756
Drug: Cefpirome 2
Normalized name: Cefpirome
DrugBank: Cefpirome (DB13682)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cefpirome 2 g intravenously
Study: 6527751
Drug: 80 mg
Normalized name: RNA 180 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 80 mg of liquid haloperidol daily
Study: 22325048
Drug: Etanercept 50
Normalized name: etanercept 50 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Etanercept 50 mg/week
Study: 21970137
Drug: Midazolam 0.05
Approvals — FDA: no, EMA: no, PMDA: no
Description: Midazolam 0.05 mg/kg (group M)
Study: 21970137
Drug: Propofol 1
Normalized name: propofol 10 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propofol 1 mg/kg (group P)
Study: 11449608
Drug: Both medications
Normalized name: Bothrops atrox venom
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both medications
Study: 16916538
Drug: 60 mg
Normalized name: opium 60 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 60 mg MPH
Study: 16916538
Drug: 90 mg
Normalized name: papain 90 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 90 mg MPH
Study: 16916538
Drug: 40 mg
Normalized name: rutin 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40 mg cocaine
Study: 3526085
Drug: Tamoxifen (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tamoxifen (10 mg orally bid)
Study: 1090132
Drug: Bendroflumethiazide, 5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bendroflumethiazide, 5 mg plus Bumetanide, 4 mg
Study: 1090132
Drug: Bumetanide, 4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bumetanide, 4 mg
Study: 1090132
Drug: Bendroflumethiazide, 5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bendroflumethiazide, 5 mg plus Spironolactone, 100 mg
Study: 23816410
Drug: Anti-tuberculous therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anti-tuberculous therapy for 8 months
Study: 14686230
Drug: Valganciclovir 900
Approvals — FDA: no, EMA: no, PMDA: no
Description: Valganciclovir 900 mg once daily
Study: 11713941
Drug: High-dose interferon
Normalized name: interferon-beta
DrugBank: Human interferon beta (DB14999)
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose interferon administered daily
Study: 11713941
Drug: High-dose interferon
Normalized name: interferon-beta
DrugBank: Human interferon beta (DB14999)
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose interferon administered three times weekly
Study: 8213711
Drug: Ursodeoxycholic acid
Normalized name: Ursodeoxycholic acid
DrugBank: Ursodeoxycholic acid (DB01586)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ursodeoxycholic acid 1000 mg/day
Study: 16753240
Drug: Quadrivalent HPV
Normalized name: HPV, quadrivalent
Approvals — FDA: no, EMA: no, PMDA: no
Description: Quadrivalent HPV (Types 6/11/16/18) L1 virus‐like particle (VLP) vaccine
Study: 26639477
Drug: Placebo formulations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo formulations
Study: 2870277
Drug: Different treatments
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Different treatments received by the first 130 patients
Study: 2870277
Drug: Different treatments
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Different treatments received by the second group of 142 patients
Study: 20083627
Drug: High-dose losartan
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose losartan (150 mg)
Study: 15235144
Drug: Iron supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Iron supplementation therapy
Study: 19260630
Drug: Group A:
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group A: 20 ml normal saline preincisional infiltration and 20 ml R0, 25% intraperitoneal
Study: 19260630
Drug: Group B:
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group B: 20 ml R0, 0.25% preincisional parietal and 20 ml normal saline intraperitoneal
Study: 12543742
Drug: Lignocaine 2%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lignocaine 2% gel
Study: 10389775
Drug: Clonidine 3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clonidine 3 microg/kg and famotidine 20 mg orally with isoflurane anesthesia
Study: 8537982
Drug: High-dose wheat
Normalized name: WHEAT
DrugBank: Wheat (DB10579)
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose wheat bran fiber (13.5 g/day)
Study: 8537982
Drug: High-dose calcium
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose calcium carbonate (1500 mg/day)
Study: 11791035
Drug: ARB alone
Normalized name: revakinagene taroretcel
Approvals — FDA: no, EMA: no, PMDA: no
Description: ARB alone (irbesartan 150 mg/day)
Study: 11791035
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of ACEI + ARB
Study: 16143731
Drug: IPSRT (Interpersonal
Approvals — FDA: no, EMA: no, PMDA: no
Description: IPSRT (Interpersonal and Social Rhythm Therapy)
Study: 19249750
Drug: Varenicline (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Varenicline (2 mg/day)
Study: 15958334
Drug: Cefazolin (single
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cefazolin (single dose) prior to TACE
Study: 11281486
Drug: No prophylactic
Approvals — FDA: no, EMA: no, PMDA: no
Description: No prophylactic antibiotics (NONE group)
Study: 8208596
Drug: Exosurf Neonatal
Normalized name: Exosurf Neonatal Powder for Intratracheal Suspension
DrugBank: Colfosceril palmitate (DB09114)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Exosurf Neonatal (5 mL/kg)
Study: 8208596
Drug: Survanta (4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Survanta (4 mL/kg)
Study: 2645569
Drug: Taurine supplementation
Normalized name: Taurine
DrugBank: Taurine (DB01956)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Taurine supplementation (45 mg/L)
Study: 2645569
Drug: Control (less
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (less than 5 mg/L taurine)
Study: 26824933
Drug: SFC 25/250 μg
Approvals — FDA: no, EMA: no, PMDA: no
Description: SFC 25/250 μg with Mini Spacer
Study: 26824933
Drug: SFC 25/250 μg
Approvals — FDA: no, EMA: no, PMDA: no
Description: SFC 25/250 μg with Aerochamber
Study: 24046993
Drug: Propofol (1-1.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propofol (1-1.5 mg/kg)
Study: 17201701
Drug: Discontinuation of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Discontinuation of major antiepileptic drugs (AEDs)
Study: 17201701
Drug: Continuation of
Normalized name: varenicline
DrugBank: Varenicline (DB01273)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Continuation of major antiepileptic drugs (AEDs)
Study: 2834746
Drug: 200 mg
Normalized name: RNA 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 mg itraconazole for 1 day
Study: 2834746
Drug: 200 mg
Normalized name: RNA 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 mg itraconazole for 2 days
Study: 31394945
Drug: Rational Emotive
Normalized name: plasma protein fraction Injection [Plasmanate]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rational Emotive Behavior Therapy (REBT)
Study: 17136583
Drug: Botulinum toxin
Normalized name: Botulinum toxin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Botulinum toxin type B (BT‐B) intravesical injections (5000 MU, 1 ml, diluted to 20 mls with normal saline, injected in 10 different sites into the detrusor)
Study: 11220879
Drug: Standard therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard therapy (ST)
Study: 22703892
Drug: Oxycodone 10mg
Normalized name: OXYCODONE 10MG/ACETAMINOPHEN 300MG TAB
DrugBank: Oxycodone (DB00497)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Oxycodone 10mg / Morphine 20mg
Study: 22703892
Drug: Oxycodone 15mg
Normalized name: oxycodone hydrochloride 15 MG [Roxicodone]
DrugBank: Oxycodone (DB00497)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Oxycodone 15mg / Morphine 30mg
Study: 22703892
Drug: Oxycodone 20mg
Normalized name: oxycodone
DrugBank: Oxycodone (DB00497)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Oxycodone 20mg / Morphine 40mg
Study: 22703892
Drug: Morphine 20mg
Normalized name: MORPHINE 20MG/NALTREXONE 0.8MG SA CAP
DrugBank: Morphine (DB00295)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Morphine 20mg and 30mg
Study: 22703892
Drug: Morphine 40mg
Normalized name: morphine sulfate 40 MG
DrugBank: Morphine (DB00295)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Morphine 40mg and Oxycodone (all doses)
Study: 16961805
Drug: Lansoprazole group:
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lansoprazole group: 7-day course of lansoprazole 30 mg, amoxicillin 750 mg, and metronidazole 250 mg, b.i.d.
Study: 16961805
Drug: Famotidine group:
Approvals — FDA: no, EMA: no, PMDA: no
Description: Famotidine group: 7-day course of famotidine 40 mg, amoxicillin 750 mg, and metronidazole 250 mg, b.i.d.
Study: 7963709
Drug: Zidovudine (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zidovudine (200 mg every 4 h)